Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Cipher Pharmaceuticals
CPH
Cipher Pharmaceuticals
Rising Medicaid Pressures And Generics Will Shrink Dermatology Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
29 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$14.00
1.9% overvalued
intrinsic discount
16 Aug
CA$14.26
Loading
1Y
-6.7%
7D
-4.6%
Author's Valuation
CA$14.0
1.9% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$14.0
1.9% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
59m
2014
2017
2020
2023
2025
2026
2028
Revenue US$59.1m
Earnings US$14.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.71%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
US$14.11m
Earnings '28
x
20.51x
PE Ratio '28
=
US$289.42m
Market Cap '28
US$289.42m
Market Cap '28
/
24.82m
No. shares '28
=
US$11.66
Share Price '28
US$11.66
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
US$9.80
Fair Value '25
US$9.80
Fair Value '25
Converted to CAD @ 1.3814 USD/CAD Exchange Rate
=
CA$13.54
Fair Value '25
